Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Apr;16(2):234-41.
doi: 10.1208/s12249-015-0313-1. Epub 2015 Mar 5.

Orally disintegrating films and mini-tablets-innovative dosage forms of choice for pediatric use

Affiliations
Review

Orally disintegrating films and mini-tablets-innovative dosage forms of choice for pediatric use

Maren Preis. AAPS PharmSciTech. 2015 Apr.

Abstract

Oral drug delivery is a non-invasive and therefore a very convenient route of administration. Orally disintegrating dosage forms, like soluble films and (mini-)tablets, appear promising for use in the pediatric population. New guidance for the development of pediatric medicines has been published, which provides considerations on how pediatric products should be designed. However, most of the considerations leave a lot of room for interpretations. Bearing in mind the different aspects discussed in the latest guideline, the use of orally disintegrating films and tablets, in particular, small-sized tablets, is discussed and reflected upon by providing evidence from the scientific literature. The available dosage forms for children are various and examples of currently licensed products for use in the pediatric population were compiled. Aspects such as the appropriateness for pediatrics, the choice of excipients, the opportunities for modified drug release preparations or fixed-dose combinations, the acceptability and palatability, and also limitations were discussed with respect to the new dosage forms of orally disintegrating films and mini-tablets. This paper points out that innovation in pediatric medicines are planned and should be encouraged; however, supported by the regulatory guidance, only general considerations are provided. Nevertheless, the guideline summarizes multiple points to consider during the development of medicines for pediatric use. Considering the scientific evidence and the regulatory guidance, orally disintegrating dosage forms, like soluble films and (mini-)tablets, offer an innovative solution for pediatric drug delivery.

PubMed Disclaimer

References

    1. Breitkreutz J, Boos J. Paediatric and geriatric drug delivery. Exp Opin Drug Deliv. 2007;4(1):37–45. doi: 10.1517/17425247.4.1.37. - DOI - PubMed
    1. Cram A, Breitkreutz J, Desset-Brèthes S, Nunn T, Tuleu C. Challenges of developing palatable oral paediatric formulations. Int J Pharm. 2009;365(1–2):1–3. doi: 10.1016/j.ijpharm.2008.09.015. - DOI - PubMed
    1. Stegemann S, Gosch M, Breitkreutz J. Swallowing dysfunction and dysphagia is an unrecognized challenge for oral drug therapy. Int J Pharm. 2012;430(1–2):197–206. doi: 10.1016/j.ijpharm.2012.04.022. - DOI - PubMed
    1. Van Riet Nales DA, Römkens EGAW, Saint-Raymond A, Kozarewicz P, Schobben AFAM, Egberts TCG, et al. Oral medicines for children in the European paediatric investigation plans. PLoS ONE. 2014;9(6):e98348. doi: 10.1371/journal.pone.0098348. - DOI - PMC - PubMed
    1. European Medicins Agency (EMA). Guideline on pharmaceutical development of medicines for paediatric use. EMA/CHMP/QWP/805880/2012 Rev. 2. 2013. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guidelin.... Accessed 14 Nov 2014.

LinkOut - more resources